240 related articles for article (PubMed ID: 26055920)
41. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
Moore TJ; Furberg CD
Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
[TBL] [Abstract][Full Text] [Related]
42. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases.
Reisinger SJ; Ryan PB; O'Hara DJ; Powell GE; Painter JL; Pattishall EN; Morris JA
J Am Med Inform Assoc; 2010; 17(6):652-62. PubMed ID: 20962127
[TBL] [Abstract][Full Text] [Related]
43. Statistical visualization for assessing performance of methods for safety surveillance using electronic databases.
Li X; Hui S; Ryan P; Rosenman M; Overhage M
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):503-9. PubMed ID: 23408560
[TBL] [Abstract][Full Text] [Related]
44. Advancing Toward a Common Data Model in Ophthalmology: Gap Analysis of General Eye Examination Concepts to Standard Observational Medical Outcomes Partnership (OMOP) Concepts.
Cai CX; Halfpenny W; Boland MV; Lehmann HP; Hribar M; Goetz KE; Baxter SL
Ophthalmol Sci; 2023 Dec; 3(4):100391. PubMed ID: 38025162
[TBL] [Abstract][Full Text] [Related]
45. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
Maro JC; Brown JS
Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
[TBL] [Abstract][Full Text] [Related]
46. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.
Lin KJ; Schneeweiss S
Clin Pharmacol Ther; 2016 Aug; 100(2):147-59. PubMed ID: 26916672
[TBL] [Abstract][Full Text] [Related]
47. Exploration of heterogeneity in distributed research network drug safety analyses.
Hansen RA; Zeng P; Ryan P; Gao J; Sonawane K; Teeter B; Westrich K; Dubois RW
Res Synth Methods; 2014 Dec; 5(4):352-70. PubMed ID: 26052957
[TBL] [Abstract][Full Text] [Related]
48. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
[TBL] [Abstract][Full Text] [Related]
49. Sensitivity analysis of methods for active surveillance of acute myocardial infarction using electronic databases.
Li X; Girman CJ; Ofner S; Shen C; Brodovicz KG; Simonaitis L; Santanello N
Epidemiology; 2015 Jan; 26(1):130-2. PubMed ID: 25390030
[TBL] [Abstract][Full Text] [Related]
50. Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.
Andrade SE; Toh S; Houstoun M; Mott K; Pitts M; Kieswetter C; Ceresa C; Haffenreffer K; Reichman ME
Matern Child Health J; 2016 Apr; 20(4):895-903. PubMed ID: 26645616
[TBL] [Abstract][Full Text] [Related]
51. Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected.
Raebel MA; Shetterly S; Lu CY; Flory J; Gagne JJ; Harrell FE; Haynes K; Herrinton LJ; Patorno E; Popovic J; Selvan M; Shoaibi A; Wang X; Roy J
Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):798-814. PubMed ID: 27146273
[TBL] [Abstract][Full Text] [Related]
52. Drug safety data mining with a tree-based scan statistic.
Kulldorff M; Dashevsky I; Avery TR; Chan AK; Davis RL; Graham D; Platt R; Andrade SE; Boudreau D; Gunter MJ; Herrinton LJ; Pawloski PA; Raebel MA; Roblin D; Brown JS
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):517-23. PubMed ID: 23512870
[TBL] [Abstract][Full Text] [Related]
53. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system.
Norén GN; Bergvall T; Ryan PB; Juhlin K; Schuemie MJ; Madigan D
Drug Saf; 2013 Oct; 36 Suppl 1():S107-21. PubMed ID: 24166228
[TBL] [Abstract][Full Text] [Related]
54. Adverse drug effect detection.
Lian Duan L; Khoshneshin M; Street WN; Liu M
IEEE J Biomed Health Inform; 2013 Mar; 17(2):305-11. PubMed ID: 24235108
[TBL] [Abstract][Full Text] [Related]
55. Building the observational medical outcomes partnership's T-MSIS Analytic File common data model.
Williams N
Inform Med Unlocked; 2023; 39():. PubMed ID: 37305615
[TBL] [Abstract][Full Text] [Related]
56. Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model.
Burkard T; López-Güell K; Gorbachev A; Bellas L; Jödicke AM; Burn E; de Ridder M; Mosseveld M; Gratton J; Seager S; Vojinovic D; Mayer MA; Ramírez-Anguita JM; Machín AL; Oja M; Kolde R; Bonadt K; Prieto-Alhambra D; Reich C; Català M
Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5809. PubMed ID: 38773798
[TBL] [Abstract][Full Text] [Related]
57. Erratum to: A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
Drug Saf; 2015 Aug; 38(8):767-8. PubMed ID: 26136091
[No Abstract] [Full Text] [Related]
58. Medical product safety surveillance: how many databases to use?
Maro JC; Brown JS; Kulldorff M
Epidemiology; 2013 Sep; 24(5):692-9. PubMed ID: 23867812
[TBL] [Abstract][Full Text] [Related]
59. Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'.
Gagne JJ; Schneeweiss S
Stat Med; 2013 Mar; 32(6):1073-4. PubMed ID: 23413214
[No Abstract] [Full Text] [Related]
60. European Health Data & Evidence Network-learnings from building out a standardized international health data network.
Voss EA; Blacketer C; van Sandijk S; Moinat M; Kallfelz M; van Speybroeck M; Prieto-Alhambra D; Schuemie MJ; Rijnbeek PR
J Am Med Inform Assoc; 2023 Dec; 31(1):209-219. PubMed ID: 37952118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
